Background: Functional alterations of innate lymphocytes, which can mount rapid immune responses and shape subsequent T cell reactions, were examined in the acute phase of ischemic stroke. Methods: Frequencies, intracellular perforin and interferon-γ (IFN-γ) expression of Vδ2 T cells, CD3+ CD56+ natural killer T (NKT)-like and NK cells were examined in the peripheral blood of 20 healthy controls and 28 patients within 6 h of the onset of acute ischemic stroke and after 72 h by flow cytometry. Cytokine production of isolated NKT-like and NK cells following in vitro activation was measured by cytometric bead array. NK cytotoxicity was examined in the peripheral blood mononuclear cells. Results: Percentages of Vδ2, NKT-like and NK cells were constant, and similar to percentages in healthy subjects. In contrast, proinflammatory intracellularIFN-γ expression by Vδ2 T cells, NKT-like cells and NK cells and IFN-γ production by isolated NK cells in culture was low at 6 h and reached the level of healthy subjects by 72 h after stroke. Production of anti-inflammatory cytokines was unaltered. Intracellular perforin expression by Vδ2 T cells, NKT-like cells and NK cells, and NK cytotoxicity was low at 6 h, and reached the level of healthy subjects by 72 h. Increases in IFN-γ and perforin expression by Vδ2 T cells correlated with clinical improvement indicated by decreases in NIHSS scores. Conclusions: Pro-inflammatory and cytotoxic responses of NK, NKT-like and Vδ2 T cells become acutely deficient in ischemic stroke, which may contribute to an increased susceptibility to infections.

Keywords:
γδ T cells, Innate immunity, NK cells, NKT cells, Stroke
1.
Davenport RJ, Dennis MS, Wellwood I, Warlow CP: Complications after acute stroke. Stroke 1996;27:415–420.
2.
Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE, Haley EC: Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998;29:447–453.
3.
Georgilis K, Plomaritoglou A, Dafni U, Bassiakos Y, Vemmos K: Aetiology of fever in patients with acute stroke. J Intern Med 1999;246:203–209.
4.
Grau AJ, Buggle F, Schnitzler P, Spiel M, Lichy C, Hacke W: Fever and infection early after ischemic stroke. J Neurol Sci 1999;171:115–120.
5.
Vargas M, Horcajada JP, Obach V, Revilla M, Cervera A, Torres F, Planas AM, Mensa J, Chamorro A: Clinical consequences of infection in patients with acute stroke: is it prime time for further antibiotic trials? Stroke 2006;37:461–465.
6.
Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H, Tilston J, Langhorne P, Stott DJ: Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke 2007;38:2284–2291.
7.
Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U: Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005;6:775–786.
8.
Chamorro A, Urra X, Planas AM: Infection after acute ischemic stroke: a manifestation of brain induced immunodepression. Stroke 2007;38:1097–1103.
9.
Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, Prass K, Meisel A: Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007;38:770–773.
10.
Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, Meisel A: Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003;198:725–736.
11.
Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, Vandenbark AA, Hurn PD: Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol 2006;176:6523–6531.
12.
Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, Kessler C, Dressel A: Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke 2008;39:237–241.
13.
Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dirnagl U, Meisel A, Meisel C: Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009;158:1184–1193. DOI: 10.1016/j.neuroscience.2008.07.044.
14.
Urra X, Cervera A, Villamor N, Planas AM, Chamorro A: Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience 2009;158:1174–1183. DOI: 10.1016/j.neuroscience.2008.06. 014.
15.
Haeusler KG, Schmidt WU, Föhring F, Meisel C, Helms T, Jungehulsing GJ, Nolte CH, Schmolke K, Wegner B, Meisel A, Dirnagl U, Villringer A, Volk HD: Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis 2008;25:50–58.
16.
Lahn M: The role of gammadelta T cells in the airways. J Mol Med 2000,78:409–425.
17.
De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Herzenberg LA, Roederer M: Ontogeny of γδT cells in humans. J Immunol 2004;172:1637–1645.
18.
Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z: γδT cells provide an early source of interferon γ in tumor immunity. J Exp Med 2003;198:433–442.
19.
Szekeres-Bartho J, Barakonyi A, Miko E, Polgar B, Palkovics T: The role of gamma/delta T cells in the feto-maternal relationship. Semin Immunol 2001;13:229–233.
20.
Kronenberg M, Gapin L: The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557–568.
21.
Tupin E, Kinjo Y, Kronenberg M: The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007;5:405–417.
22.
Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687–1696.
23.
Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS: Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 1995;86:3493–3499.
24.
Hammond KJ, Godfrey DI: NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 2002;59:353–363.
25.
Hammond KJ, Kronenberg M: Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol 2003;15:683–689.
26.
Miyake S, Yamamura T: NKT cells and autoimmune diseases: unraveling the complexity. Curr Top Microbiol Immunol 2007;314:251–267.
27.
Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A: Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647–4650.
28.
Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421–2438.
29.
Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633–640.
30.
Strowig T, Brilot F, Münz C: Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008;180:7785–7791.
31.
Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528–530.
32.
Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650–652.
33.
Podack ER, Hengartner H, Lichtenheld MG: A central role of perforin in cytolysis? Annu Rev Immunol 1991;9:129–157.
34.
Griffith GM, Mueller C: Expression of perforin and granzymes in vivo: potential markers for activated cytotoxic cells. Immunol Today 1991;12:415–419.
35.
Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806–3813.
36.
Jordán J, Segura T, Brea D, Galindo MF, Castillo J: Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008;14:3549–3564.
37.
Molnar T, Peterfalvi A, Szereday L, Pusch G, Szapary L, Komoly S, Bogar L, Illes Z: Deficient leukocyte antisedimentation is related to post-stroke infections and outcome. J Clin Pathol 2008;61:1209–1213.
38.
Hauben E, Schwartz M: Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol Sci 2003;24:7–12.
39.
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49–55.
40.
Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR, Weiner H, Schwartz M: Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001;21:3740–3748.
41.
Guth L, Zhang Z, DiProspero NA, Joubin K, Fitch MT: Spinal cord injury in the rat: treatment with bacterial lipopolysaccharide and indomethacin enhances cellular repair and locomotor function. Exp Neurol 1994;126:76–87.
42.
Nishimura M, Mitsunaga S, Akaza T, Mitomi Y, Tadokoro K, Juji T: Protection against natural killer cells by interferon-γ treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression. Immunology 1994;83:75–80.
43.
Kubista B, Trieb K, Herbacek I, Micksche M: Effect of granulocyte-macrophage colony-stimulating factor on natural-killer cell mediated cytotoxicity. Int J Biochem Cell Biol 2003;35:1056–1060.
44.
Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971–979.
45.
Young HA, Bream JH: IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 2007;316:97–117.
46.
Young HA, Hardy KJ: Role of interferon-γ in immune cell regulation. J Leukoc Biol 1995;58:373–381.
47.
Gardiner CM, Reen DJ: Differential cytokine regulation of natural killer cell-mediated necrotic and apoptotic cytotoxicity. Immunology 1998;93:511–517.
48.
Prass K, Braun JS, Dirnagl U, Meisel C, Meisel A: Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 2006;37:2607–2612.
49.
Kipnis J, Mizrahi T, Hauben E, Shaked I, Shevach E, Schwartz M: Neuroprotective autoimmunity: naturally occurring CD4+ CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci USA 2002;99:15620–15625.
50.
Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR: Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 1999;22:295–299.
51.
Butovsky O, Hauben E, Schwartz M: Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7–2 (CD86) and prevention of cyst formation. FASEB J 2001;15:1065–1067.
52.
Barouch R, Schwartz M: Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity. FASEB J 2002;16:1304–1306.
53.
Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, Svenningsson A, Lindå H, van Der Meide PH, Cullheim S, Olsson T, Piehl F: Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283–5291.
54.
Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75–85.
55.
Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, Göhler J, Bereswill S, Göbel U, Werencke KD, Wolf T, Arnold G, Halle E, Volk H-D, Dirnagl U, Meisel A: Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One 2008;3:1–12.
56.
Schwarz S, Al-Shajlawi F, Sick C, Meairs S, Hennerici MG: Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke. Stroke 2008;39:1220–1227.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.